Prion inhibition

Details Prion inhibition Prion inhibition

2003-11-28

2009-06-23

Nickol, Gary B. (Department: 1648)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

C424S248100, C424S139100, C424S141100, C530S388150, C530S324000

Reexamination Certificate

active

07550144

ABSTRACT:
The invention relates to the use of an agent such as an antibody capable of reacting with PrP in the prevention of prion replication in a subject, in the treatment or prevention of prion infection, in the treatment or prevention of neuropathology associated with prion infection or in the preparation of a medicament for the treatment or prevention of prion disease. Furthermore, the invention relates to methods of treatment of prion disease, methods of inhibiting prion replication and antibodies for use in such methods.

REFERENCES:
patent: 2003/0049249 (2003-03-01), Weissmann et al.
patent: WO-97/10505 (1997-03-01), None
patent: WO-98/37210 (1998-08-01), None
patent: WO-00/78344 (2000-12-01), None
patent: WO-02/087502 (2002-11-01), None
patent: WO-03/025181 (2003-03-01), None
patent: WO-03/080665 (2003-10-01), None
Peretz et al (2001) Nature. 412:739-743.
White et al (2003) Nature. 422: 80-83.
Paul, Fundamental Immunology, 3rd Edition, 1993, pp. 292-295, under the heading “Fv Structure and Diversity in Three Dimensions”.
Rudikoff et al (Proc. Natl. Acad. Sci. USA, 79(6):1979-1983, Mar. 1982).
MacCallum et al (J. Mol. Biol., 262, 732-744, 1996).
Casset et al (Biochemical and Biophysical Research Communications, 307:198-205, 2003).
Coleman P. M. (Research in Immunology, 145:33-36, 1994).
Altschul et al., J. Mol. Biol., 215:403-410 (1990).
Anstee et al., Immunology, 74:197-205 (1991).
Avent et al., Biochem. J., 256:1043-1046 (1988).
Beringue et al., Brain, 126:2065-2073 (2003).
Brown, Neurology, 58:1720-1725 (2002).
Collins et al., Ann. Neurol., 52:503-506 (2002).
Dickinson et al., J. Comp. Pathol., 78:293-299 (1968).
Farquhar et al., Lancet, 353:117 (1999).
Jackson et al., Biochim. Biophys. Acta, 1431:1-13 (1999).
Sethi et al., Lancet, 360:229-230 (2002).
Sigurdsson et al., Neurosci. Lett., 336: 185-187 (2003).
Souan et al., Eur. J. Immunol., 31:2338-2346 (2001).
Wadsworth et al., Lancet, 358:171-180 (2001).
Westaway et al., Trends Biochem Sci., 27(6):301-307 (2002).
Will et al., Lancet, 347:921-925 (1996).
Bard et al., Nat. Med., 6(8):916-919 (2000).
Beringue et al., J. Virol., 74(12):5432-5440 (2000).
Brandner et al., Nature, 379:339-343 (1996).
Brown et al., Nat. Med., 5(11):1308-1312 (1999).
Bruce et al., Nature, 389(6650):498-501 (1997).
Bueler et al., Nature, 356:577-582 (1992).
Collinge et al., Nature, 383:685-690 (1996).
Devereux et al., Nucleic Acids Res., 12(1):387-395 (1984).
Enari et al., Proc. Natl. Acad. Sci. USA, 98(16):9295-9299 (2001).
Heppner et al., Science, 294:178-182 (2001).
Hill et al., Nature, 389:448-450 (1997).
Ingrosso et al., J. Virol., 69(1):506-508 (1995).
Jackson et al., Science, 283:1935-1937 (1999).
Klein et al., Nat. Med., 4(12):1429-1433 (1998).
Korth et al., Proc., Natl. Acad. Sci, USA, 98(17):9836-9841 (2001).
McKenzie et al., J. Virol., 68(11):7534-7536 (1994).
Montrasio et al., Science, 288:1257-1259 (2000).
Peretz et al., Nature, 412:739-743 (2001).
Prusiner, Proc. Natl. Acad. Sci. USA, 95:13363-13383 (1998).
Sigurdsson et al., Am. J. Pathol., 161(1):13-17 (2002).
Thompson et al., Nucleic Acids Res., 22(22):4673-4680 (1994).
White et al., Nature, 422:80-83 (2003).

Affiliated with

Also associated with

Rating

Prion inhibition does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Prion inhibition, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Prion inhibition will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4102223